OTCMKTS:BIXT Bioxytran Q1 2024 Earnings Report $0.09 0.00 (-3.11%) As of 09/15/2025 03:58 PM Eastern ProfileEarnings History Bioxytran EPS ResultsActual EPS-$0.01Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABioxytran Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABioxytran Announcement DetailsQuarterQ1 2024Date3/22/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Bioxytran Earnings HeadlinesBioxytran Unveils Revolutionary Precision Diagnostics on Tissue OxygenationAugust 15, 2025 | globenewswire.comBioxytran’s Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection TreatmentAugust 8, 2025 | finance.yahoo.comAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.September 16 at 2:00 AM | Porter & Company (Ad)Bioxytran's Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection TreatmentAugust 7, 2025 | globenewswire.comBioxytran Secures a Source of GMP Quality Camel HemoglobinJune 18, 2025 | globenewswire.comBioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation That Measures Oxygenation Uptake During StrokesJune 3, 2025 | finance.yahoo.comSee More Bioxytran Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bioxytran? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioxytran and other key companies, straight to your email. Email Address About BioxytranBioxytran (OTCMKTS:BIXT) is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings. Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release. These formulations are engineered to minimize oxidative stress and inflammation while enhancing tissue recovery. The company maintains a patent portfolio covering key geographies, including North America, Europe, and Asia, and is actively exploring collaborative partnerships to support development and potential global commercialization. Originating from foundational work in synthetic oxygen therapeutics, Bioxytran has transitioned from early-stage research into a specialized biopharmaceutical developer. The management team brings together expertise in biotechnology R&D, regulatory strategy, and manufacturing scale-up. Bioxytran continues to pursue strategic alliances and funding initiatives to advance its mission of delivering innovative oxygen-based therapies that improve patient outcomes in critical therapeutic areas.View Bioxytran ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner Upcoming Earnings FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
